Get the latest news on NKGen Biotech stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on NKGNW performance

Latest NKGen Biotech Stock News | OTC:NKGNW | Benzinga

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

Comments

NKGen Biotech Stock News

News

Latest NKGen Biotech Stock News | OTC:NKGNW | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga